← Human Trials & Peer-Reviewed Studies
Modulation of miR-29a and miR-29b Expression and Their Target Genes Related to Inflammation and Renal Fibrosis by an Oral Nutritional Supplement with Probiotics in Malnourished Hemodialysis Patients.
Plain-language guide to PMID 38256206 (2024): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 38256206
- Journal
- International journal of molecular sciences
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Sasso CV et al. (11 authors)
- DOI
- 10.3390/ijms25021132
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
Malnutrition is prevalent in patients with chronic kidney disease (CKD), especially those on hemodialysis.
The researchers performed a randomized, multicenter, parallel-group trial in malnourished hemodialysis patients with three groups (1: control (C) individualized diet (n = 11); 2: oral nutritional supplement (ONS) + placebo (ONS-PL) (n = 10); and 3: ONS + probiotics (ONS-PR) (n = 10)); the trial was open regarding the intake of ONS or individualized diet recommendations but double-blinded for the intake of probiotics.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled, multicenter and parallel-group.
The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).
The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.
Running at several centres spread the Copper (Supplement) study over different clinics and patient groups.
What Was Measured
MiRNAs and gene expression levels were analyzed by RT-qPCR at baseline and after 3 and 6 months.
The subject headings attached to it are Fibrosis, Inflammation, Kidney Diseases, Malnutrition, MicroRNAs, Renal Dialysis and Probiotics.
The authors tagged it with the keywords chronic kidney disease, circulating miRNAs, gene expression, hemodialysis, oral nutritional supplement and renal fibrosis.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
The publication is from 2024 (International journal of molecular sciences), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.